No immediate trading catalyst from this filing. Monitor for actual clinical data readouts, financing events, or regulatory milestones specific to CMND-100. The broader regulatory tailwind is positive for the sector but does not change the company's near-term risk profile.
Price Chart
Executive Summary
Clearmind Medicine issued a press release commending recent federal regulatory developments supporting psychedelic-based therapies, including FDA guidance and inter-agency collaborations. The filing contains no company-specific material events, financial data, or pipeline updates — it is a non-substantive commentary on broader industry momentum.
Key Facts
- Press release dated July 17, 2026, titled 'Clearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Health and Addiction'.
- Highlights final FDA guidance on psychedelic clinical investigations, a planned public hearing, and MOUs involving HHS, VA, FDA, NIDA, ARPA-H, and HRSA.
- No company-specific clinical results, financial data, guidance changes, or capital events disclosed.
- Lead candidate CMND-100 (MEAI) remains in FDA-cleared Phase I/IIa trials for Alcohol Use Disorder.
Financial Impact
No financial impact disclosed; filing is a non-material commentary.
Risk Factors
- Forward-looking statements carry no guarantee of regulatory or commercial success.
- Company remains pre-revenue with a $2M market cap and high cash burn risk.
- No concrete progress on its own pipeline beyond acknowledging federal momentum.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-079147 |
| Document: ea029839201ex99-1.htm | 0001213900-26-079147 |
| Document: 0001213900-26-079147-index-headers.html | 0001213900-26-079147 |
| Document: 0001213900-26-079147-index.html | 0001213900-26-079147 |
| Document: 0001213900-26-079147.txt | 0001213900-26-079147 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $5.92 | awaiting T+60 | — | $5.97 (+0.80%) |
Oct 27, 2026 today | Press Release | $6.50 | awaiting T+60 | — | $5.97 (−8.20%) |
Oct 16, 2026 11d ago | 6-K | $6.00 | awaiting T+60 | — | $5.97 (+0.55%) |
Oct 13, 2026 14d ago | 6-K | $6.23 | awaiting T+60 | — | $5.97 (−4.22%) |
Oct 8, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $5.97 (−9.59%) |
Oct 7, 2026 20d ago | 6-K | $6.60 | awaiting T+60 | — | $5.97 (−9.59%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $5.97 (+602.04%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $5.97 (+602.04%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $5.97 (−13.06%) |
Sep 14, 2026 6w ago | 6-K | $0.9440 | awaiting T+60 | — | $5.97 (+532.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers